Novel Therapies for Hemophilia: What Does the Evidence Show?

The expanding number of hemophilia therapies has led to a complicated treatment decision-making process. There are many barriers to implementation of these newer therapies, including gaps in clinicians' knowledge regarding the latest data on the safety and efficacy of these therapies.

In the first module of this CME Outfitters 3-part snack series on prior authorization for hemophilia, expert faculty discuss new and emerging therapies for hemophilia and the evidence for use in patients with hemophilia.

We encourage learners to complete all 3 CME Snacks in this series to receive a Certificate of Excellence in Prior Authorization.

At the end of this CE activity, participants should be able to:
-Apply the latest clinical evidence on the efficacy and safety of new and emerging therapies to treatment decisions for individuals with hemophilia.

The following learning objectives pertain only to those requesting CNE or CPE credit:
-Identify the latest clinical evidence on the efficacy and safety of new and emerging therapies for treatment decisions for individuals with hemophilia.